NovaBay Pharmaceuticals Inc
NBY0.737USD
-0.023-3.00%
收盘 02/09, 16:00（美东）报价延迟15分钟
694.01总市值
0.12市盈率 TTM
关于 NovaBay Pharmaceuticals Inc 公司
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc简介
公司代码NBY
公司名称NovaBay Pharmaceuticals Inc
上市日期Oct 26, 2007
CEOKazley (Michael John)
员工数量14
证券类型Ordinary Share
年结日Oct 26
公司地址2000 Powell St Ste 1150
城市EMERYVILLE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编94608-1804
电话15108998800
网址https://novabay.com/
公司代码NBY
上市日期Oct 26, 2007
CEOKazley (Michael John)
NovaBay Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+841.00%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-513.00%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-26.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+841.00%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-513.00%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-26.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
收入明细
FY2025Q3
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
521.00K
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 2月5日 周四
更新时间: 2月5日 周四
持股股东
股东类型
持股股东
持股股东
占比
R01 Fund LP
45.02%
Framework Ventures Management LLC
45.02%
Lazar (David Elliot)
5.06%
The Vanguard Group, Inc.
1.45%
Poplar Point Capital Management LLC
0.81%
其他
2.63%
持股股东
持股股东
占比
R01 Fund LP
45.02%
Framework Ventures Management LLC
45.02%
Lazar (David Elliot)
5.06%
The Vanguard Group, Inc.
1.45%
Poplar Point Capital Management LLC
0.81%
其他
2.63%
股东类型
持股股东
占比
Corporation
90.04%
Individual Investor
5.07%
Investment Advisor
1.83%
Hedge Fund
0.81%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.01%
其他
2.18%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
41
3.14M
2.49%
+1.61M
2025Q3
38
1.37M
22.81%
-82.54K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
84.49K
0.07%
+84.22K
+31191.85%
Sep 30, 2025
Poplar Point Capital Management LLC
1.02M
0.81%
--
--
Oct 15, 2025
Geode Capital Management, L.L.C.
51.72K
0.04%
+17.90K
+52.92%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
公告日期
除权除息日
类型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
